ライフサイエンスコーパス: hospital discharge

1 admission for at least 4 h (from birth until hospital discharge).

2 lity of life at 2-3 months and 6 months post-hospital discharge.

3 on and the earlier of postoperative day 5 or hospital discharge.

4 mary outcome was PR uptake within 28 days of hospital discharge.

5 reports (86%) were issued prior to death or hospital discharge.

6 ciated with lower probability of survival to hospital discharge.

7 impairment 14 days after ICU discharge or at hospital discharge.

8 tis who chooses to delay surgery until after hospital discharge.

9 e need for elective revascularization before hospital discharge.

10 d also focus on antimicrobial prescribing at hospital discharge.

11 -IRA lesions in an elective procedure before hospital discharge.

12 ex) were assessed at ICU awakening, ICU, and hospital discharge.

13 ion among all health services received after hospital discharge.

14 Rankin Scale was prospectively determined at hospital discharge.

15 after study drug administration and prior to hospital discharge.

16 Patients with HF who were aged 75 years at hospital discharge.

17 nce, discontinuation of corticosteroids, and hospital discharge.

18 associated with good neurologic function at hospital discharge.

19 are beneficiaries in GWTG-HF who survived to hospital discharge.

20 ive mechanical ventilation, and death before hospital discharge.

21 ds of midodrine prescription at both ICU and hospital discharge.

22 istence of acquired functional impairment at hospital discharge.

23 impairments and was suitable for use before hospital discharge.

24 op cognitive impairment that persists beyond hospital discharge.

25 italization, or mortality within 6 months of hospital discharge.

26 four survivors of EVD at 1 or 3 months after hospital discharge.

27 reated with quinidine invariably survived to hospital discharge.

28 ual care, and followed up for 6 months after hospital discharge.

29 symptoms extending beyond intensive care and hospital discharge.

30 rtic valve replacement through 90 days after hospital discharge.

31 in care, and care engagement at the time of hospital discharge.

32 ioning and functional status, measured after hospital discharge.

33 es were associated with improved survival to hospital discharge.

34 have a slower weight gain and head growth at hospital discharge.

35 to breastfeed immediately after birth and at hospital discharge.

36 ould also focus on antibiotic-prescribing at hospital discharge.

37 ollowed up for a maximum of 15 days or until hospital discharge.

38 erformance Category score of 1-2 at or after hospital discharge.

39 ion, and mortality events within 6 months of hospital discharge.

40 primary endpoint was time from first dose to hospital discharge.

41 ne oxygenation and 352 (59.4%) died prior to hospital discharge.

42 swallowing examinations and follow-up until hospital discharge.

43 s associated with AF within 90 days of index hospital discharge.

44 48, and 72 hours after injury, as well as at hospital discharge.

45 es throughout pregnancy and occurring before hospital discharge.

46 ardiac arrest is associated with survival to hospital discharge.

47 of acute respiratory failure survivors after hospital discharge.

48 they arrived in the inpatient ward and until hospital discharge.

49 days covered (PDC) during 180 days following hospital discharge.

50 ssion from 2006 through 2009 and survived to hospital discharge.

51 Recovery was defined as reversal at hospital discharge.

52 f pulmonary rehabilitation within 90 days of hospital discharge.

53 d for 24 hours, and 4488 (36.2%) survived to hospital discharge.

54 oints: baseline, 1 month, and 3 months after hospital discharge.

55 Primary outcome was survival to hospital discharge.

56 male, and 24256 patients (22.4%) survived to hospital discharge.

57 sociated with better neurological outcome at hospital discharge.

58 from critical illness and persisting beyond hospital discharge.

59 rmine both the cause and time to death after hospital discharge.

60 ical research evaluating ARF survivors after hospital discharge.

61 morbidity was associated with longer time to hospital discharge.

62 The primary outcome is diagnosis of HO at hospital discharge.

63 ng acute respiratory failure survivors after hospital discharge.

64 comes are associated with recovery status at hospital discharge.

65 admission, and lasted from 1 to 30 days, ICU/hospital discharge.

66 tenuation of improvement persists long after hospital discharge.

67 ional status (modified Rankin Score, 0-3) at hospital discharge.

68 aboratory reports returned prior to death or hospital discharge.

69 atients with a final disposition of death or hospital discharge.

70 44% of patients (11/25) survived to hospital discharge.

71 ogical outcome (modified Rankin scale <3) at hospital discharge.

72 l frequently prescribed to inpatients and at hospital discharge.

73 poor (Cerebral Performance Category 3-5) at hospital discharge.

74 solving inflammation that persists following hospital discharge.

75 om coronavirus disease 2019 (COVID-19) after hospital discharge.

76 is model may be useful in decision making at hospital discharge.

77 ansport and lower probability of survival to hospital discharge.

78 nd 60.4% (131/217) patients have survived to hospital discharge.

79 therapy contacts supporting device use after hospital discharge.

80 rly ART and care engagement, particularly at hospital discharge.

81 m on quality of life at 1 and 3 months after hospital discharge.

82 y assessment, at ICU discharge, and prior to hospital discharge.

83 nts enroll in pulmonary rehabilitation after hospital discharge.

84 ority of fluoroquinolone DOTs occurred after hospital discharge.

85 prescription for opioids in the 7 days after hospital discharge.

86 In the 182 days after myocardial infarction hospital discharge, 15.4% of beneficiaries discontinued

87 Of the 920 patients who survived to hospital discharge, 171 (19%) were readmitted within 30

88 ity and mortality in the region of interest, Hospital discharge (2001-2013) and mortality (2003-2014)

89 26 ng/mL were associated with lower rates of hospital discharge (22 [88%] of 25 patients with low con

90 orhoods had lower adjusted survival rates to hospital discharge (25%-50% black: odds ratio, 0.76; 95%

91 for Physical Function in ICU Test-scored at hospital discharge (27%).

92 t stages of treatment: treatment initiation, hospital discharge, 3-month follow-up, and long-term fol

93 At hospital discharge, 34% (311/909) of patients were conti

94 delivering by ERCS to breastfeed at birth or hospital discharge (63.6%, n = 14,906 versus 54.5%, n =

95 Of the 1,966 patients surviving until hospital discharge, 89.4% of FH patients and 89.9% of no

96 In the months after hospital discharge, a team of nurses, social workers, an

97 s to describe fluoroquinolone-prescribing at hospital discharge across the Veterans Health Administra

98 s to describe fluoroquinolone prescribing at hospital discharge across the Veterans Health Administra

99 to conduct a time-series analysis of monthly hospital discharges across age groups for acute gastroen

100 nonculprit lesion PCI planned to occur after hospital discharge (actual time: median 23 days), CV dea

101 ssociated with higher odds of death prior to hospital discharge (adjusted odds ratio for each 5 addit

102 iated with persistent acquired impairment at hospital discharge (adjusted odds ratio, 1.29; 95% CI, 1

103 oor perfusion were more likely to survive to hospital discharge (adjusted odds ratio, 2.31; 95% CI, 1

104 The overall survival to hospital discharge after OHCA treated with PAD showed a

105 death (HR, 0.82 [95% CI, .55-1.22]), time to hospital discharge alive (HR, 1.07 [95% CI, .91-1.26]),

106 d use was associated with better survival to hospital discharge and 1-year survival.

107 CCI (at hospital discharge and after 6 months) was the result of

108 with significantly lower kidney function at hospital discharge and after a median follow-up of 820 d

109 fety, survival, and functional assessment at hospital discharge and at 3 months and 6 months after di

110 ciated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 m

111 es, Six-Item Screener telephone assessments, hospital discharge and death certificate codes, and the

112 hree cohorts were ascertained from the state hospital discharge and death registries; subsequent canc

113 ed with a three-fold increase in the odds of hospital discharge and favorable neurologic status on di

114 alculated separately from the time of PCI to hospital discharge and from hospital discharge to 1-year

115 median number of days between the second HF hospital discharge and hospice enrollment was 45.

116 on of newly initiated midodrine upon ICU and hospital discharge and identify risk factors associated

117 nstrates that the combination of state-level hospital discharge and mortality data can be used to ide

118 ry results with clinical outcomes, including hospital discharge and mortality.

119 At hospital discharge and one-year post-disease onset, adve

120 , but excluding death), and were assessed at hospital discharge and one-year post-disease onset.

121 iated with greater likelihood of survival to hospital discharge and survival with favorable neurologi

122 They were more likely to survive to hospital discharge and survive with favorable neurologic

123 We found no interaction between survival to hospital discharge and the initial rhythm.

124 sons, mortality risk remains high even after hospital discharge and there is a need to identify those

125 nalyzed the differences between survivors to hospital discharge and those who died.

126 Mean hospital discharges and days were measured, both society

127 d impairment at PICU discharge persisting to hospital discharge), and "no acquired impairment." CT sc

128 ts received a prescription for opioids after hospital discharge, and 2.6% met criteria for persistent

129 Forty-seven percent survived to hospital discharge, and 43% survived to discharge with f

130 with the presence of neurologic deficits at hospital discharge, and at 6, 12, and 24 months postdisc

131 plus up to 30 days after discharge), time to hospital discharge, and hospital readmission within 30 d

132 Polypharmacy is common both at admission and hospital discharge, and its prevalence is rising over ti

133 ldren 1-5 months of age, AZM administered at hospital discharge, and the combination of MDA and post-

134 The primary outcome was survival to hospital discharge, and the secondary outcome was return

135 The primary outcome was survival to hospital discharge, and the secondary outcome was surviv

136 n postsurgical disability in the month after hospital discharge, and years of education.

137 Secondary outcomes were OOPHE, hospital discharges, and quality of service provision.

138 s associated with a reduction in survival to hospital discharge (AOR, 0.71; 95% CI, 0.55-0.92; P=0.00

139 As hospital discharge approaches, clinicians should use bri

140 nary complications, readmission, and delayed hospital discharge are directly attributable to having a

141 boprophylaxis in COVID-19 patients following hospital discharge are required.

142 sequently have elevated rates of death after hospital discharge as a result of secondary organ damage

143 ion as the primary end point and survival at hospital discharge as a secondary end point.

144 categorized cause of death in the year after hospital discharge as cardiovascular, cancer, infection-

145 espiratory failure survivors' outcomes after hospital discharge, as related to the 19 preliminary out

146 Following 1877 hospital discharges associated with COVID-19, 9 episodes

147 Overall hospital discharges averaged 12.8 per 100 persons in the

148 The estimated date of hospital discharge based on early measures of motor acti

149 elated problems continue within 2-4 weeks of hospital discharge, be prioritized among high-risk patie

150 (42.8%) in the control group had died before hospital discharge (between-group difference, -0.3 perce

151 ty and short-term outcomes for contusions at hospital discharge.(C) RSNA, 2019Online supplemental mat

152 Functionally favorable survival to hospital discharge (Cerebral Performance Category 1 or 2

153 The increase in hospital discharges coded with congenital cytomegaloviru

154 Linkage Study) to calculate annual rates of hospital discharges coded with-and individuals aged youn

155 miologic studies of sepsis to date have used hospital discharge codes and have suggested dramatic inc

156 .9 assessed at 2 subsequent examinations and hospital discharge codes through 2012.

157 rillation significantly improved survival to hospital discharge compared with standard ACLS treatment

158 ssociated with a 10-fold higher mortality at hospital discharge compared with STEMI without SCA.

159 the shortest procedure duration and time-to-hospital discharge compared with the other techniques (P

160 er odds of neurologically intact survival to hospital discharge compared with those treated during th

161 Participants were linked to all-payer hospital discharge data (1995 through 2014 or 2015) and

162 The German nationwide hospital discharge data (diagnosis-related groups-statis

163 ssachusetts, and New Jersey) using all-payer hospital discharge data (January 1, 2011-September 30, 2

164 tScan 2014 Research Databases, combined with hospital discharge data from the 2014 Healthcare Cost an

165 ctronic Health Record (EHR) to State Uniform Hospital Discharge Data Set (UHDDS).

166 om 2006 to 2016 and the concurrent Tennessee Hospital Discharge Data System.

167 rom birth certificates and maternally linked hospital discharge data.

168 es, 10th Edition, coding strategy for use in hospital discharge data.

169 re reviewed using New York State's mandatory hospital discharge database.

170 dentified via record linkage with nationwide hospital discharge database.

171 Based on the French administrative hospital-discharge database, the study collected informa

172 Based on the French administrative hospital-discharge database, the study collected informa

173 east 7 days, the mean error of Prediction of Hospital Discharge Date at day 7 was 0.231 +/- 22.98 day

174 ly measures of motor activity and the actual hospital discharge date were compared by a Hierarchical

175 activity allowed for accurate prediction of hospital discharge date.

176 ion and rehospitalization within 6 months of hospital discharge decreased from 19% to 17% and 37% to

177 erate anemia had resolved within 6 months of hospital discharge decreased from 42% to 34% (P < 0.001)

178 ry outcome was LTCI at 3- and 12 months post-hospital discharge defined by the Repeatable Battery for

179 e followed for incident dementia (defined by hospital discharge diagnosis or acetylcholinesterase inh

180 s: A codesigned education video delivered at hospital discharge did not improve posthospitalization P

181 mized trials, we observed that use of a post-hospital discharge EDT strategy for a 4-to-6-week period

182 een 7 and 14 days of life, with follow-up to hospital discharge ending December 12, 2017.

183 other causes of death) up to 10 years after hospital discharge following adversity-related (self-inf

184 ion to rivaroxaban 10 mg or placebo daily at hospital discharge for 45 days.

185 nitiation among Medicare beneficiaries after hospital discharge for a myocardial infarction may help

186 nd hemorrhage appear to be similar following hospital discharge for COVID-19, emphasizing the need fo

187 offending (primary outcome) within 1 year of hospital discharge for inpatients or clinical contact wi

188 ctors of high-intensity statin use following hospital discharge for myocardial infarction (MI) betwee

189 asis on improving transitions at the time of hospital discharge for patients with HF.

190 ization Project of 14 states to evaluate all hospital discharges for patients aged 0 to 17 years (her

191 and outcomes (death, mechanical ventilation, hospital discharge) for these groups, as well as cumulat

192 mortality of diabetic patients, censored at hospital discharge, for patients with relative hypoglyce

193 ive analysis of adult (>=18 years) inpatient hospital discharges from a large hospital system in the

194 We performed a retrospective cohort study of hospital discharges from October 20, 2015, to October 19

195 f opioid prescriptions in trauma patients at hospital discharge has not been explored.

196 ation was not associated with survival after hospital discharge (hazard ratio, 0.99; 95% CI, 0.76-1.2

197 ) treated with oral anticoagulant therapy at hospital discharge (HR, 1.03; 95% CI, 0.73-1.46) nor was

198 %) treated with dual antiplatelet therapy at hospital discharge (HR, 1.04; 95% CI, 0.74-1.46) nor was

199 RV remodeling were more likely to survive to hospital discharge (HR: 1.39; 95% CI: 1.01 to 1.90; p =

200 to assess fluoroquinolone appropriateness at hospital discharge (i.e. post-discharge) were performed

201 tcome measures included rates of survival to hospital discharge, ICU and hospital lengths of stay, du

202 to assess fluoroquinolone appropriateness at hospital discharge (ie, postdischarge) were performed ac

203 Dofetilide was discontinued before hospital discharge in 46 (27%) because of QT prolongatio

204 , we compared the differences in survival to hospital discharge in adults with shock-refractory ventr

205 n could reduce morbidity and mortality after hospital discharge in children younger than 5 years of a

206 observational studies reporting survival to hospital discharge in OHCA patients where an automated e

207 ived IMV, and survived at least 7 days after hospital discharge in Ontario, Canada over a 26-month pe

208 and complexity of CAD and report survival to hospital discharge in patients experiencing refractory V

209 Outpatient diagnoses and follow-up after hospital discharge in primary care declined substantiall

210 was common in ICU patients, sustained until hospital discharge in the majority of affected patients,

211 ignificant trend toward improved survival to hospital discharge in the subgroup with shockable initia

212 delirium and decreased quality of life after hospital discharge in young children.

213 -nine secondary outcomes were analyzed up to hospital discharge, including death and BPD at 36 weeks'

214 (hemoglobin levels between 7 and 10 g/dL) at hospital discharge increased from 20% to 25% (P < 0.001)

215 Death prior to hospital discharge, infection more than 3 days after bir

216 At hospital discharge, interleukin-6, -8, and -10 retained

217 However, the impact of CDI after hospital discharge is poorly understood.

218 Their risk of death in the decade after hospital discharge is twice as high as that of adolescen

219 ngly, patients admitted to an ICU survive to hospital discharge; many with ongoing medical needs.

220 ty and short-term outcomes for contusions at hospital discharge.Materials and MethodsIn this retrospe

221 Children's perinatal risk was evaluated at hospital discharge, maternal PTSD symptoms were assessed

222 ovir or oral valganciclovir once daily until hospital discharge (n = 84) or to receive matching place

223 me of death or readmission within 30 days of hospital discharge occurred in 20 patients (18%) in the

224 Good neurologic function at hospital discharge occurred in 30% of patients in the en

225 which included 27 705 patients, survival to hospital discharge occurred in 4.0% of patients who unde

226 eases in high-intensity statin use following hospital discharge occurred over this period among patie

227 failure predicted midodrine continuation at hospital discharge (odds ratio, 1.49 [1.05-2.12]).

228 f a thrombotic event, which were censored at hospital discharge or 30 days after PCC administration.

229 s, early IFN-alpha2b was not associated with hospital discharge or computed tomography (CT) scan impr

230 American sites; follow-up until the date of hospital discharge or death [regardless of when either e

231 nitoring and had a definitive disposition of hospital discharge or death.

232 d that remdesivir improves time to recovery (hospital discharge or no supplemental oxygen requirement

233 d for all arrhythmias was from surgery until hospital discharge or postoperative day 10.

234 p, and their course from diagnosis to either hospital discharge or to improvement in symptoms.

235 fferent between functional outcome groups at hospital discharge (p = 0.019 pineal; p = 0.008 septum),

236 care group were readmitted within 7 days of hospital discharge (p = 0.02).

237 (1.9%) placebo-treated patients survived to hospital discharge (P=0.24).

238 Before hospital discharge, participants were randomly assigned

239 9] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients [MARINER]; NCT02111564).

240 9] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients) studied acutely ill medical

241 nalysis of enrolled patients who survived to hospital discharge, patients randomized to the ICU recov

242 d impairment at PICU discharge recovering by hospital discharge), "persistent acquired impairment" (a

243 Exposure was quarter year of hospital discharge; postpublication was defined as Janua

244 The relationship between hospital discharge practices and readmission rates is th

245 ine and artesunate either in mortality or in hospital discharge rate, with hazard ratios (HRs) of 1.0

246 erence was found in terms of mortality or in hospital discharge rates between artesunate- and quinine

247 Intensive care unit and hospital discharge rates were 66% and 46%, respectively,

248 By linking statewide hospital discharge records with cancer registry data in

249 ke events were assessed by record linkage to hospital discharge registries.

250 e identified through linkage of the national Hospital Discharge Registry, national Cause of Death Reg

251 ty may predict inpatient clinical course and hospital discharge remains unknown.

252 al regurgitation, which were identified from hospital discharge reports or primary care records.

253 e, but the majority of patients surviving to hospital discharge returned home.

254 ent (community children) or a week following hospital discharge (severe malaria) and 6, 12, and 24 mo

255 There was discordance in the hospital discharge status (alive or dead) for only 0.47%

256 improved resolution of organ dysfunction and hospital discharge status.

257 ssociated with significantly higher rates of hospital discharge (subdistribution hazard [95% CI], 1.6

258 No effects were detected on hospital discharges, suggesting that SMSXXI might not ha

259 nurse-led self-care education, a structured hospital discharge summary, a family physician follow-up

260 ys) and 108472 hospital stays (2010 National Hospital Discharge Survey).

261 Overall hospital discharge survival was 23%.

262 utcomes: patient-related (mortality, ICU and hospital discharge), symptom-related (mechanical ventila

263 5% CI, 0.70, 0.93]; P=0.004) of surviving to hospital discharge than those who were initially pulsele

264 re in the 90 days subsequent to an inpatient hospital discharge that included an explicit sepsis code

265 Before hospital discharge, the SBML and usual training groups t

266 mortality were identified from 1 year after hospital discharge through December 2014.

267 ascularization between operator cohorts from hospital discharge to 1-year follow-up (adjusted hazard

268 e time of PCI to hospital discharge and from hospital discharge to 1-year follow-up.

269 ness were "days to ESD" (number of days from hospital discharge to first ESD contact; n=6222), "rehab

270 factors, and continuation of treatment after hospital discharge to improve long-term outcomes.

271 Post-hospital discharge to nonhome location was also signific

272 assessed risk-adjusted rates of survival to hospital discharge using multilevel Poisson regression m

273 l assessments, beginning within 2-4 weeks of hospital discharge, using the following screening tools:

274 ress disorder symptomatology was assessed at hospital discharge via the Posttraumatic Stress Disorder

275 Survival to hospital discharge was 100%.

276 Survival to hospital discharge was 3.8% for patients who underwent i

277 Mortality rate at hospital discharge was 4.0% in the nonSCA group versus 3

278 as 3675 of 8754 (41.9%) and survival rate at hospital discharge was 788 of 8754 (9%), ranging from 33

279 igh statin adherence over the year following hospital discharge was defined as proportion of days cov

280 Outcome at hospital discharge was evaluated with the Glasgow Outcom

281 nders, we found that the rate of survival to hospital discharge was lower during nights than during d

282 The rate of survival to hospital discharge was lower for pediatric CPR events oc

283 Survival to hospital discharge was observed in one (7%) of 15 patien

284 The survival rate on hospital discharge was remarkably high, with 15 cases (8

285 Median time to hospital discharge was shorter in the NAC arm (9 days; I

286 ient Sample, a representative sample of U.S. hospital discharges, was used to determine costs of eye

287 In 447 women who were continent at hospital discharge, we recorded 24 cases of post-repair

288 Benchmark values at 30 days after hospital discharge were </=55.7% and </=30.8% for overal

289 Sequential samples at 1 and 3 months after hospital discharge were also tested for SARS-CoV-2 RBD a

290 kidney disease (CKD) within 1 year following hospital discharge were determined.

291 veloped stress hyperglycemia and survived to hospital discharge were eligible.

292 uced posttraumatic stress symptomatology) at hospital discharge were included.

293 ale scores at admission, PICU discharge, and hospital discharge were obtained for all patients.

294 A total of 2471 hospital discharges were identified.

295 tal of 361,323 severe sepsis or septic shock hospital discharges were included.

296 very 6 hours until 48 postoperative hours or hospital discharge, whichever occurred first.

297 italization with major infection, defined by hospital discharge with a diagnosis code for urinary tra

298 aths or neonatal unit admission up to infant hospital discharge with a non-inferiority hypothesis (no

299 Secondary outcome was survival to hospital discharge with favorable neurological outcome,

300 A total of 75% of VTE events occurred after hospital discharge, with a 19.5-day median time to VTE.